Camp4 Therapeutics (CAMP) director awarded 28,000 stock options

Rhea-AI Filing Summary

Camp4 Therapeutics Corp director Douglas E. Williams received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $4.34 per share and expire on June 9, 2036. All 28,000 underlying shares vest together on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, assuming continued service through that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider WILLIAMS DOUGLAS E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	28,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 28,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 28,000 options Exercise price: $4.34 per share Underlying shares: 28,000 shares +2 more

5 metrics

Option grant size 28,000 options Stock Option (Right to Buy) granted to director

Exercise price $4.34 per share Conversion or exercise price of the options

Underlying shares 28,000 shares Common stock underlying the stock options

Expiration date June 9, 2036 Option expiration

Post-grant derivative holdings 28,000 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), exercise price, vest in their entirety, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "4.3400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in their entirety financial

"The shares underlying the option vest in their entirety on the earlier of the first anniversary..."

annual meeting of stockholders financial

"the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILLIAMS DOUGLAS E

(Last) (First) (Middle)

C/O CAMP4 THERAPEUTICS CORPORATION

ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.34	06/10/2026		A		28,000		(1)	06/09/2036	Common Stock	28,000	$0	28,000	D

Explanation of Responses:

1. The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date.

Remarks:

	/s/ Josh Mandel-Brehm, as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Camp4 Therapeutics (CAMP) disclose in this Form 4 for Douglas E. Williams?

Camp4 Therapeutics disclosed that director Douglas E. Williams received a grant of stock options for 28,000 shares of common stock. These options are a compensation award, not an open-market trade, and give him the right to buy shares at a fixed exercise price.

How many Camp4 Therapeutics (CAMP) shares are covered by the new stock options?

The new stock option grant covers 28,000 shares of Camp4 Therapeutics common stock. Following this award, the filing shows holdings of 28,000 derivative securities from this grant, reflecting the full amount tied to this single option grant.

What is the exercise price and expiration date of Douglas E. Williams’ Camp4 options?

The options have an exercise price of $4.34 per share and expire on June 9, 2036. This means he can choose to buy up to 28,000 shares at $4.34 any time before the expiration date, once vested and subject to plan terms.

When do the Camp4 Therapeutics stock options granted to Douglas E. Williams vest?

The options vest in full on the earlier of the first anniversary of the grant date or the date of Camp4’s next annual meeting of stockholders. Vesting requires that Douglas E. Williams continue serving the company through the applicable vesting date.

Is this Camp4 Therapeutics (CAMP) Form 4 a stock purchase or a compensation grant?

This Form 4 reports a compensation grant, not an open-market stock purchase. Douglas E. Williams received stock options as a grant or award, giving him the right to buy 28,000 shares at $4.34, subject to vesting and plan conditions.